In race to lead the TIGIT pack in I/O, Roche delivers positive PhII data — but big questions linger
Expectations over Roche’s anti-TIGIT drug tiragolumab have been growing steadily in the buildup to ASCO. As the lead drug in the field pursuing second-generation status in immuno-oncology, it marks a potential major advance over the first generation of I/O drugs in the market.
And on Wednesday’s data drop, the pharma giant’s big sub Genentech delivered the data, which was quickly — and not always favorably — compared closely with Merck’s dominant drug Keytruda.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.